Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study - Summary - MDSpire

Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study

  • By

  • Daniele Noviello

  • María Chaparro

  • Chiara Viganò

  • Andreas Blesl

  • Brigida Barberio

  • Henit Yanai

  • Ambrogio Orlando

  • Rocío Ferreiro-Iglesias

  • Cristina Bezzio

  • Alessandra Zilli

  • Tamás Molnár

  • Cristian Gheorghe

  • Francesco Conforti

  • Tommaso Innocenti

  • Simone Saibeni

  • Peter Bossuyt

  • Raquel Oliveira

  • Anna Maria Carvalhas Gabrielli

  • Alessandra Losco

  • Sophie Vieujean

  • Enrico Tettoni

  • Lorena Pirola

  • Silvia Calderone

  • Maya Kornowski Cohen

  • Gabriele Dragoni

  • Timo Rath

  • Manuel Barreiro-de Acosta

  • Edoardo Vincenzo Savarino

  • Javier P Gisbert

  • Maurizio Vecchi

  • Raja Atreya

  • Flavio Caprioli

  • April 1, 2025

  • 0 min

Share

Objective:

To assess the effectiveness and safety of fidaxomicin for Clostridioides difficile infection (CDI) in patients with inflammatory bowel disease (IBD) and its impact on IBD outcomes.

Key Findings:
  • CDI recurrence rate was 10% at week 8.
  • Sustained response rate was 82% at week 12.
  • Patients with a first CDI episode had a lower recurrence rate (4.3%) compared to those with previous episodes (16%).
  • 48% of patients required IBD therapy escalation.
  • Five patients underwent colectomy, and one unrelated death occurred.
Interpretation:

Fidaxomicin was found to be effective and safe for treating CDI in IBD patients, with better outcomes in CDI-naïve patients, potentially influencing short-term IBD management.

Limitations:
  • Retrospective design may introduce bias.
  • Limited data on long-term outcomes and adverse events.
Conclusion:

Fidaxomicin demonstrates efficacy and safety in treating CDI among IBD patients, with implications for improving IBD outcomes, particularly in those experiencing their first CDI episode.

Original Source(s)

Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study

  • by Daniele Noviello, María Chaparro, Chiara Viganò, Andreas Blesl, Brigida Barberio, Henit Yanai, Ambrogio Orlando, Rocío Ferreiro-Iglesias, Cristina Bezzio, Alessandra Zilli, Tamás Molnár, Cristian Gheorghe, Francesco Conforti, Tommaso Innocenti, Simone Saibeni, Peter Bossuyt, Raquel Oliveira, Anna Maria Carvalhas Gabrielli, Alessandra Losco, Sophie Vieujean, Enrico Tettoni, Lorena Pirola, Silvia Calderone, Maya Kornowski Cohen, Gabriele Dragoni, Timo Rath, Manuel Barreiro-de Acosta, Edoardo Vincenzo Savarino, Javier P Gisbert, Maurizio Vecchi, Raja Atreya, Flavio Caprioli

  • April 1, 2025

Related Content

Metabolic and Structural Alterations Linked to Mice's Vulnerability to Primary Echinostoma caproni Infections

Genes Predict Bowel Disease Severity

Large study suggests genetic risk scores could help doctors identify patients who need closer monitoring and earlier treatment

  • March 12, 2026

  • 2 min
Integrating Double-Balloon Enteroscopy into the Diagnostic Pathway for Suspected Small Bowel Crohn’s Disease: A Retrospective Study from a Tertiary Care Center